Neuroscience
At Johnson & Johnson, we are dedicated to alleviating the burden and challenges of serious neuropsychiatric diseases. Our mission is to create innovative solutions that can not only improve but truly transform the lives of individuals living with mental illness. We are committed to enhancing the prevention, diagnosis, and treatment of mental health disorders, making a meaningful difference for those affected.
Did you know that over 40% of Irish adults have a mental health disorder? [1] The impact of mental illness is profound and far-reaching. That’s why we value an ongoing dialogue with patients and their caregivers—it’s essential for deepening our understanding of what it means to live with mental health conditions. By listening to the experiences of those directly affected, we are better equipped to provide the support and solutions needed to drive real change.
Did you know that over 40% of Irish adults have a mental health disorder? [1] The impact of mental illness is profound and far-reaching. That’s why we value an ongoing dialogue with patients and their caregivers—it’s essential for deepening our understanding of what it means to live with mental health conditions. By listening to the experiences of those directly affected, we are better equipped to provide the support and solutions needed to drive real change.
Ireland has one of the highest mental illness rates in Europe, with around 150,000 people each year living with severe depression [2][3]. Yet many feel isolated and uninformed due to stigma, preventing them from seeking help.[3][4] Talking Depression aims to encourage people to find the right support and to continue conversations about depression.
On this website, you’ll find expert advice from healthcare professionals, real-life stories from people living with depression, and guidance on treatment options and available supports. Click below to explore the resources available.
On this website, you’ll find expert advice from healthcare professionals, real-life stories from people living with depression, and guidance on treatment options and available supports. Click below to explore the resources available.
You are now leaving J&J Innovative Medicine Ireland
The site you’re being redirected to is an external website where this Privacy Policy does not apply. Please click below to continue to that site.
References
- Hyland P, Vallières F, Shevlin M, Bentall RP, Butter S, Hartman TK, Karatzias T, Martinez AP, McBride O, Murphy J, Fox R. State of Ireland’s mental health: findings from a nationally representative survey. Epidemiol Psychiatr Sci. 2022 Jul https://pubmed.ncbi.nlm.nih.gov/35773999/ Accessed October 2024.
- CSO, Irish Health Survey 2015, see ‘Table 6: All persons aged 15 years and over classified by mental health status in previous two weeks, 2015’. 3% of respondents reporting as experiencing moderately severe or severe depression is estimated MDD patient population. Estimated 150,000 people with MDD is 3% of projected population in 2020 (4.98m). Available at: https://www.cso.ie/en/releasesandpublications/ep/p-ihs/irishhealthsurvey2015/ct/ Accessed: October 2024.
- Aware’s national survey reveals high rates of depression and anxiety. Available here: https://www.aware.ie/national-survey-2023/#:~:text=The%20survey%20revealed%20that%20depression,cent)%20stating%20an%20official%20diagnosis Accessed: October 2024.
- Patient research on major depressive disorder carried out by Ipsos MRBI between 2nd October – 3rd November 2020 on behalf of Janssen Sciences Ireland.